Core Insights - Geron is focusing on RYTELO as a standard-of-care option for second-line patients, emphasizing its market potential in lower-risk myelodysplastic syndromes (MDS) [1][3] - The company is implementing a "3D surround sound" marketing strategy, increasing investment in effective channels such as digital promotion and educational platforms [1][2] - Geron anticipates RYTELO net revenue of $220 million to $240 million for 2026, with consistent quarter-over-quarter demand growth expected [5] Commercial Performance - RYTELO's fourth-quarter 2025 net revenue was $48 million, aligning with expectations, while the full-year revenue reached $184 million [6] - Demand for RYTELO grew by 9% in the fourth quarter compared to the third quarter, with a 13% increase in prescribing accounts, expanding to approximately 1,300 accounts [4][6] - The company reported that first- and second-line patient starts were about 30% on a rolling 12-month basis [4] Market Dynamics - Geron sees favorable market conditions for second-line, lower-risk MDS, with an estimated eligible patient population of around 8,000 in the U.S. [3] - The competitive landscape is shifting, with key opinion leaders preferring imetelstat over ESAs as a second-line option due to the dominance of luspatercept in the first line [8] Financial Overview - Total operating expenses for 2025 were approximately $255 million, with guidance for 2026 set at $230 million to $240 million, reflecting a year-over-year reduction [13][14] - The company has access to an additional $125 million in capital through an amendment to its loan agreement, with plans for a new shelf registration [14] Research and Development - Geron is supporting over 10 investigator-sponsored trials and real-world evidence initiatives, with initial data expected in the second half of 2026 [10][11] - The IMpactMF trial is fully enrolled and projected to reach its interim analysis in the second half of this year, with overall survival as the primary endpoint [12] International Strategy - Geron has received European approval for RYTELO but is cautious about its near-term impact due to funding limitations [16] - The company is focused on U.S. growth while exploring opportunities in Europe, including understanding health technology assessment processes [16]

Corporate Presentation Financial Discipline and Opportunistic Innovation * RYTELO® (imetelstat) is approved in the U.S. and the EU for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. See U.S. Prescribing Information and Medication Guide: https://pi.geron.com/products/US/pi/rytelo_pi.pdf; see Summary of Product Characteristics for RYTELO in the EU: https://pi.geron.com/products/rytelo/eu/rytelo_smpc_eu.pdf o $220M-$240M in expected ...

Summary of Geron Corporation Conference Call Company Overview - **Company**: Geron Corporation - **Core Asset**: Imetelstat (commercial name: Rytelo), the first approved telomerase inhibitor for lower-risk myelodysplastic syndromes (MDS) [2][5] Key Points Company and Product Positioning - Geron is a commercial-stage hematology company with an approved product, Rytelo, launched in the US and approved in Europe [2][5] - The company aims to help patients in the relapse, lower-risk MDS population, which has limited treatment options [2][5] Leadership and Experience - Harout Semerjian, the new CEO, has over 30 years of experience in biopharma, particularly in oncology and hematology [4][5] - The CEO's previous experience includes launching multiple oncology drugs, which aligns with Geron's current needs [4][5] Market Performance and Challenges - Rytelo's growth has stalled, with net revenue around $50 million, despite strong phase 3 data [6][9] - The disconnect between the drug's efficacy and sales performance is attributed to: - Initial patient selection being primarily late-line patients, who are harder to treat [8][9] - Limited clinical experience among US hematologists at launch, as most trial data was generated outside the US [9][10] Strategic Initiatives - The company is focusing on increasing awareness and education among physicians about Rytelo's efficacy and appropriate patient management [12][13] - Efforts are being made to shift Rytelo's utilization from later lines of treatment to earlier lines, as indicated by clinical guidelines [12][21] Patient Population and Treatment Dynamics - The real-world patient population primarily consists of third-line and fourth-line patients, which affects treatment duration and outcomes [17][18] - The NCCN guidelines have recently been updated to position Rytelo favorably in treatment protocols, moving it ahead of other therapies like HMAs [18][19][21] Competitive Landscape - Luspatercept's approval as a front-line therapy for RS-positive patients may impact patient flow into later lines of treatment, creating opportunities for Rytelo as a second-line option [30][31] - Physicians' treatment decisions are influenced by baseline transfusion burden, with Rytelo being the only effective option for heavily transfused patients [37][38] Future Outlook - Geron anticipates growth in 2026, supported by a robust cash balance and strategic initiatives aimed at enhancing market presence [11][40][41] - The company has submitted five abstracts for the upcoming ASH conference, including data on cytopenia correlating with response and long-term survival benefits [41][42] International Expansion - Geron is exploring commercialization plans in Europe, including launching under named patient programs and engaging in HTA conversations [50][51] Additional Insights - The company is committed to educating the market about Rytelo's unique mechanism of action and the importance of managing cytopenias effectively [40][41] - There is a focus on building partnerships with both community and academic medical centers to enhance Rytelo's adoption [27][28]